Topic: multiple sclerosis
Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.
Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.
A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.
Mavenclad helped Merck KGaA's neuroscience portfolio grow 2.3% in the third quarter, even in the face of Rebif's 15% year-over-year sales decline.
Biogen's MS business has been treading water and its top-selling Tecfidera might face early generics. But now a follow-up med has nabbed FDA approval.
Genentech has launched its first consumer campaign for multiple sclerosis drug Ocrevus, with emphasis on a particular cohort of patients: millennials.
Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.
Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.
New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.
A post hoc analysis found 75% of patients showed no increase in disability five years after treatment with Mavenclad.